Determination of Impurities in New Promising Antioxidants Bis-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]sulfide and Dodecyl(3,5-dimethyl-4-hydroxybenzyl)sulfide

Introduction. Dodecyl(3,5-dimethyl-4-hydroxybenzyl)sulfide (T1) and bis-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]sulfide (T2) are the collaborative development of Novosibirsk State Pedagogical University and Novosibirsk Research Institute of Antioxidants. It was revealed in several experiments and research works that these substances have antioxidant, anti-inflammatory, hepatoprotective, cytoprotective, haemorheological activities. These facts make the objects of study promising medicinal antioxidant drugs. Consequently it’s necessary for the future production quality control to have standards and analytical methods for substances analysis.

Aim. Impurities methods development and validation for the new biologically active substances T1 and T2.

Materials and methods. HPLC method with UV-detection on 278 nm was carried out for the determination of impurities in objects of study. HPLC analysis were performed on ZORBAX SB-C18 (5 μm, 150 × 4,6 mm) column with isocratic regimen and with use of the acetonitrile:water mixture (T1) or acetonitrile (T2) as a mobile phase.

Results and discussion. It was find out, that T1 has two unidentified impurities with concentration not more than 0,1 % during the shelf life. The chromatogramm of T2 has a peak of by-product of synthesis T2 – bis-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]disulfide (T2-DS). Biologically safety of T2-DS was demonstrated in the previous works and the concentration of T2-DS was established to be not more, than 2,5 %. Furthermore, there was the one more unidentified impurity with concentration less, than 0,1 % on the chromatogram of T2. The developed HPLC methods were validated on characteristics «specificity», «linearity», «precision», «limit of quantification», «accuracy», «range».

Conclusion. Methods for the determination of impurities in T1 and T2 were validated on the listed parameters. All the results meet the acceptance criteria: peaks on the chromatogramms are clearly separated; the correlation coefficients (r) are not more, than 0,980; accuracy was proved by linearity parameters; the value of the relative standard deviation is less, than 5 %; the intermediate precision for the both methods was proved by Fisher’s criterion and Student’s t-test.

1. Bakhtina I. A., Antip’eva E. V., Prosenko A. E. Streltsova G. P., Dushkin M. I., Zenkov N. K., Men’shchikova E. B., Ragino Yu. I. Effect of the antioxidant «thiophan» on antioxidative stress parameters in ischaemic heart disease. Byulleten’ SO RAMN. 2000;(3–4):24–29. (In Russ.)

2. Fridlyand I. F., Prosenko A. E., Klepikova S. Yu., Kandalintseva N. V., Leplina O. Yu., Tikhonova M. A., Ostanin A. A., Chernykh E. R. Effect of antioxidants on the functional activity of peripheral blood mononuclear cells of patients with viral hepatitis C. Meditsinskaya immunologiya = Medical Immunology. 2001;3(2):243. (In Russ.)

3. Plotnikov M. B., Prosenko A. E., Smol’yakova V. I., Ivanov I. S., Chernysheva G. A., Kandalintseva N. V. Synthesis and antioxidant activity of 3,5-dimethyl-4-hydroxybenzylthiododecane. Khimiko-farmatsevticheskiy zhurnal = Pharmaceutical chemistry journal. 2010;44(3):65–67. (In Russ.)

4. Men’shchikova E. B., Lankin V. Z., Kandalintseva N. V. Fenol'nye antioksidanty v biologii i meditsine [Phenolic antioxidants in biology and medicine]. Saarbrucken: LAP LAMBERT Academic Publishing; 2012. 488 p. (In Russ.)

5. Borovskaja T. G., Gol’dberg E. D., Shchemerova Ju. A., Pakhomova A. V., Perova A. V., Prosenko A. E., Djubchenko O. I. Sredstvo dlya korrektsii narusheniy zhenskoy reproduktivnoy funktsii, vyzvannykh tsitostaticheskim vozdeystviem [Means for correcting disorders of female reproductive function caused by cytostatic effect]. Patent RUS № 2367420 C1. 20.09.2009. Available at: https://new.fips.ru/iiss/document.xhtml?faces-redirect=true&id=a0a3f5f82b5424e5337046838c394e0a. Accessed: 04.10.2021. (In Russ.)

6. Prosenko A. E., Gross M. A., Kandalintseva N. V., Tolstikova T. G., Sorokina I. V. Sredstvo dlya korrektsii tsitotoksicheskikh effektov paraneoplasticheskikh protsessov i khimioterapii, obladayushchee protivoopukholevoy aktivnost'yu [Agent for correcting cytotoxic effects of paraneoplastic processes and chemotherapy showing anticancer activity]. Patent RUS № 2447888 C1. 20.04.2012. Available at: https://new.fips.ru/iiss/document.xhtml?faces-redirect=true&id=c9dbc6a5ec333ebf1998a2e91bdc6654. Accessed: 04.10. 2021. (In Russ.)

7. Plotnikov M. B., Smol’jakova V. I., Ivanov I. S., Chernysheva G. A., Prosenko A. E., Gross M. A., Boyko M. A. Sredstvo, obladayushchee antiagregantnoy, umen'shayushchey povyshennuyu vyazkost' krovi i antitrombogennoy aktivnost'yu [Remedy having antiaggregant activity, activity decreasing blood hyperviscosity and antithrombogenic activity]. Patent RUS № 2368376 C1. 27.09.2009. Available at: https://new.fips.ru/iiss/document.xhtml?faces-redirect=true&id=2dd769e1785fe39dfd1f744dee2cafa8. Accessed: 04.10. 2021. (In Russ.)

8. Voevoda T. V., Tolstikova T. G., Sorokina I. V. Study of toxic effect of new phenolic antioxidant CO-3 in subchronic experiment. Eksperimental’naya i klinicheskaya farmakologiya. 2000;63(4):57–60. (In Russ.)

9. Chernysheva G. A., Gurto R. V., Khazanov, V. A., Prosenko A. E., Kandalintseva N. V. Pharmacokinetics of thiophane upon intragastric administration. Pharmaceutical chemistry journal. 2010;44(4):171–174. DOI: 10.1007/s11094-010-0424-7.

10. Okamoto M. Assay validation and technology transfer: Problems and solutions. Journal of Pharmaceutical and Biomedical Analysis. 2014;87:308–12. DOI: 10.1016/j.jpba.2013.06.028.

11. Sahu P. K., Ramisetti N. R., Cecchi T., Swain S., Patro C. S., Panda J. An overview of experimental designs in HPLC method development and validation. Journal of Pharmaceutical and Biomedical Analysis. 2018;147:590–611. DOI: 10.1016/j.jpba.2017.05.006.

12. Epshtein N. A. Validation of Analytical Procedures: Graphic and Calculated Criteria for Assessment of Methods Linearity in Practice. Drug development and registration. 2019;8(2):122–30. DOI: 10.33380/2305-2066-2019-8-2-122-130.

13. Epshtein N. A., Sevast’yanova V. L., Koroleva A. I. Validation of Related-Substances Determination Methods for Detecting Unidentified Substances. Pharmaceutical chemistry journal. 2020;54(9):959–967. DOI: 10.1007/s11094-020-02303-x.

14. Raposo F., Ibelli-Bianco C. Performance parameters for analytical method validation: Controversies and discrepancies among numerous guidelines. Trends in Analytical Chemistry. 2020;129:115913. DOI: 10.1016/j.trac.2020.115913.